Immuneering (IMRX) 25th Annual Needham Virtual Healthcare Conference summary

Key clinical results and mechanisms

• Reported nearly double the expected 12-month overall survival in first-line pancreatic cancer, with 64% OS at 12 months versus 35% for standard of care.

• Atebimetinib employs three mechanisms: durable tumor shrinkage, preservation of body mass, and minimized side effects, supporting improved survival.

• 84% of evaluable patients in phase II maintained or gained weight, counteracting cachexia, a key factor in survival.

• Excellent tolerability profile, with adverse events mainly attributable to chemotherapy, not the investigational drug.

• Data from an older patient population (median age 69) showed robust survival outcomes.

Deep Cyclic Inhibition and differentiation

• Deep Cyclic Inhibition delivers intense, daily pulses of MEK inhibition, allowing sensitive and resistant tumor cells to compete, delaying resistance.

• This approach contrasts with chronic inhibition, which quickly selects for resistant cells and leads to tumor relapse.

• The pulsatile regimen spares healthy cells, reducing side effects and supporting quality of life.

• Literature supports that maintaining body mass and performance status directly correlates with improved survival.

• The drug’s three-pronged mechanism is unique compared to other therapies that focus solely on tumor shrinkage.

Competitive landscape and future plans

• Head-to-head comparisons suggest atebimetinib offers similar or better efficacy with fewer side effects than competitors, notably Revolution Medicines.

• Calls for more transparent data from competitors to enable fair comparisons.

• Upcoming data updates include expanded cohort survival results and ctDNA analysis at AACR, highlighting resistance mechanisms.

• Phase III MAPKeeper-301 trial is fully funded, global, and randomized, with OS as the primary endpoint; first patient dosing expected mid-year.

• Regulatory alignment achieved, with top-line results expected about two years after first patient dosing.